Kaneko Tetsuharu, Kanno Chihiro, Yamazaki Morio, Yaginuma Sadanoshin
Department of Dentistry and Oral Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Natl J Maxillofac Surg. 2024 May-Aug;15(2):316-318. doi: 10.4103/njms.njms_14_24. Epub 2024 Jul 24.
Most tongue squamous cell carcinoma (TSCC) classified as T3 require reconstructive surgery, which inevitably causes problems with oral functions. We propose new induction chemotherapy using intra-arterial infusion for TSCC classified as T3 to avoid reconstructive surgery. This chemotherapy regimen consists of intra-arterial infusion of docetaxel and cisplatin and systemic administration of 5-fluorouracil. As a result of this treatment, the therapeutic effect was a complete response in five patients and a partial response in one patient, and the overall response rate was 100%. All six patients underwent partial resection because their tumors shrank with this induction chemotherapy. In addition, adverse events of grade 3 or more did not occur in all six patients. The median follow-up duration for all patients was 34 months, and they are alive. This intra-arterial chemotherapy regimen was shown to be highly efficacious and safe.
大多数分类为T3的舌鳞状细胞癌（TSCC）需要进行重建手术，这不可避免地会导致口腔功能出现问题。我们提出对分类为T3的TSCC采用动脉内灌注进行新辅助化疗，以避免进行重建手术。这种化疗方案包括动脉内灌注多西他赛和顺铂以及全身给予5-氟尿嘧啶。经过这种治疗，5例患者达到完全缓解，1例患者部分缓解，总缓解率为100%。所有6例患者均接受了部分切除术，因为他们的肿瘤在这种新辅助化疗后缩小了。此外，所有6例患者均未发生3级或以上的不良事件。所有患者的中位随访时间为34个月，他们均存活。这种动脉内化疗方案显示出高效且安全。
